313 related articles for article (PubMed ID: 33708204)
1. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis.
Fan Y; Li Y; Chu Y; Liu J; Cui L; Zhang D
Front Immunol; 2021; 12():608498. PubMed ID: 33708204
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
3. Cage Environment Regulates Gut Microbiota Independent of Toll-Like Receptors.
Lipinski JH; Zhou X; Gurczynski SJ; Erb-Downward JR; Dickson RP; Huffnagle GB; Moore BB; O'Dwyer DN
Infect Immun; 2021 Aug; 89(9):e0018721. PubMed ID: 33941577
[TBL] [Abstract][Full Text] [Related]
4. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
Caputi V; Giron MC
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
[TBL] [Abstract][Full Text] [Related]
5. Is it possible to intervene early cirrhosis by targeting toll-like receptors to rebalance the intestinal microbiome?
Zhang J; Zao X; Zhang J; Guo Z; Jin Q; Chen G; Gan D; Du H; Ye Y
Int Immunopharmacol; 2023 Feb; 115():109627. PubMed ID: 36577151
[TBL] [Abstract][Full Text] [Related]
6. Interaction between gut microbiota and toll-like receptor: from immunity to metabolism.
Yiu JH; Dorweiler B; Woo CW
J Mol Med (Berl); 2017 Jan; 95(1):13-20. PubMed ID: 27639584
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Cario E
Curr Opin Support Palliat Care; 2016 Jun; 10(2):157-64. PubMed ID: 26986508
[TBL] [Abstract][Full Text] [Related]
8. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
[TBL] [Abstract][Full Text] [Related]
9. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
10. The gut-liver axis in immune remodeling of hepatic cirrhosis.
Guan H; Zhang X; Kuang M; Yu J
Front Immunol; 2022; 13():946628. PubMed ID: 37408838
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
[TBL] [Abstract][Full Text] [Related]
13. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
[TBL] [Abstract][Full Text] [Related]
14. How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology.
Frosali S; Pagliari D; Gambassi G; Landolfi R; Pandolfi F; Cianci R
J Immunol Res; 2015; 2015():489821. PubMed ID: 26090491
[TBL] [Abstract][Full Text] [Related]
15. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.
Seo YS; Shah VH
Clin Mol Hepatol; 2012 Dec; 18(4):337-46. PubMed ID: 23323248
[TBL] [Abstract][Full Text] [Related]
16. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
17. The Role of the Gut Microbiome in Liver Cirrhosis Treatment.
Lee NY; Suk KT
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379148
[TBL] [Abstract][Full Text] [Related]
18. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
[TBL] [Abstract][Full Text] [Related]
19. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial proteins: intestinal guards to protect against liver disease.
Hendrikx T; Schnabl B
J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
